par Navez, Julie ;Iesari, Samuele;Kourta, Dhoha;Baami-Mariza, Kente;Nadiri, Marwan;Goffette, Pierre;Baldin, Paméla;Ackenine, Kevin;Bonaccorsi-Riani, Eliano;Ciccarelli, Olga;Coubeau, Laurent;Moreels, Tom;Lerut, Jan Paul
Référence Transplant international, 34, 2, page (245-258)
Publication Publié, 2021-02-01
Référence Transplant international, 34, 2, page (245-258)
Publication Publié, 2021-02-01
Article révisé par les pairs
Résumé : | Biliary tract complications (BTCs) still burden liver transplantation (LT). The wide reporting variability highlights the absence of systematic screening. From 2000 to 2009, simultaneous liver biopsy and direct biliary visualization were prospectively performed in 242 recipients at 3 and 6 months (n = 212, 87.6%) or earlier when indicated (n = 30, 12.4%). Median follow-up was 148 (107–182) months. Seven patients (2.9%) experienced postprocedural morbidity. BTCs were initially diagnosed in 76 (31.4%) patients; 32 (42.1%) had neither clinical nor biological abnormalities. Acute cellular rejection (ACR) was present in 27 (11.2%) patients and in 6 (22.2%) BTC patients. Nine (3.7%) patients with normal initial cholangiography developed BTCs after 60 (30–135) months post-LT. BTCs directly lead to 7 (2.9%) re-transplantations and 14 (5.8%) deaths resulting in 18 (7.4%) allograft losses. Bile duct proliferation at 12-month biopsy proved an independent risk factor for graft loss (P = 0.005). Systematic biliary tract and allograft evaluation allows the incidence and extent of biliary lesions to be documented more precisely and to avoid erroneous treatment of ACR. The combination ‘abnormal biliary tract-canalicular proliferation’ is an indicator of worse graft outcome. BTCs are responsible for important delayed allograft and patient losses. These results underline the importance of life-long follow-up and appropriate timing for re-transplantation. |